Colistin

Generic Name: Colistin

Brand Names: Cortisporin-TC

Drug Type: Small Molecule

Chemical Formula: C_₅₂H_₉₈N_₁₆O_₁₃

CAS Number: 1066-17-7

Unique Ingredient Identifier: Z67X93HJG1

Background: Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.

Indication: For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.

Associated Conditions: Ear infection bacterial, External ear infection NOS

Clinical Trials

Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem

Phase 4

Completed

Conditions: Gram-Negative Bacterial Infections

Interventions: Drug: Colistin
Drug: Meropenem

First Posted Date: 2012-11-22

Last Posted Date: 2017-04-12

Lead Sponsor: Mical Paul

Target Recruit Count: 406

Registration Number: NCT01732250

Locations: 🇮🇱
Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
🇮🇱
Rambam Health Care Center, Haifa, Israel
🇬🇷
Laikon Hosptial, Athens, Greece

and more 4 locations

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

Phase 3

Completed

Conditions: Pneumonia
Blood Stream Infection

Interventions: Drug: colistin and meropenem
Drug: colistin and placebo

First Posted Date: 2012-05-15

Last Posted Date: 2022-11-14

Lead Sponsor: University of Michigan

Target Recruit Count: 467

Registration Number: NCT01597973

Locations: 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Jackson Memorial Hospital-Jackson Health System, Miami, Florida, United States
🇺🇸
Beaumont Health System, Royal Oak, Michigan, United States

and more 16 locations

Colistin and Rifampicin for MDR-Acinetobacter

Phase 3

Completed

Conditions: Infection Due to Resistant Bacteria
Pneumonia, Ventilator-Associated
Hospital Acquired Pneumonia
Infection of Bloodstream
Infectious Disease of Abdomen

Interventions: Drug: Colistin
Drug: Rifampicin

First Posted Date: 2012-04-16

Last Posted Date: 2012-04-16

Lead Sponsor: University of Campania "Luigi Vanvitelli"

Target Recruit Count: 210

Registration Number: NCT01577862

Efficacy of Ascorbic Acid for Prevention of Colistin-Associated Nephrotoxicity

Phase 3

Conditions: Drug Safety

Interventions: Drug: Colistin + Ascorbic acid
Drug: Colistin

First Posted Date: 2011-12-30

Last Posted Date: 2011-12-30

Lead Sponsor: Mahidol University

Target Recruit Count: 54

Registration Number: NCT01501968

Locations: 🇹🇭
Siriraj Hospital, Bangkok, Thailand

Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii

Phase 3

Conditions: Drug Safety

Interventions: Drug: colistin plus fosfomycin
Drug: colistin

First Posted Date: 2011-02-17

Last Posted Date: 2011-12-29

Lead Sponsor: Mahidol University

Target Recruit Count: 92

Registration Number: NCT01297894

Locations: 🇹🇭
Siriraj Hospital, Bangkok, Thailand

Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

Phase 3

Conditions: Drug Safety

Interventions: Drug: Colistin plus Rifampicin
Drug: Colistin

First Posted Date: 2011-02-17

Last Posted Date: 2012-01-02

Lead Sponsor: Mahidol University

Target Recruit Count: 130

Registration Number: NCT01297855

Locations: 🇹🇭
Division of Infectious disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand

Trial of Colistin Versus Meropenem in Ventilator-associated Pneumonia (VAP) (CR-GNB)

Phase 3

Completed

Conditions: Ventilator-associated Bacterial Pneumonia

Interventions: Drug: Colistin
Drug: Meropenem

First Posted Date: 2011-02-09

Last Posted Date: 2016-02-03

Lead Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Target Recruit Count: 232

Registration Number: NCT01292031

Locations: 🇬🇷
Sotiria Hospital, Medical School University of Athens, Athens, Greece
🇬🇷
General Hospital of Larissa, Thessalia University, Athens, Greece
🇮🇹
AO Ospedale Niguarda Ca Granda Milano, Milan, Italy

and more 30 locations

A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).

Not Applicable

Completed

Conditions: Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia

Interventions: Drug: PO Garamycin 80mg x 4/d
Drug: Colistin (Polymyxin E) 100mg x 4/d
Drug: both medications
Drug: will not receive PO treatment

First Posted Date: 2010-12-24

Last Posted Date: 2017-04-28

Lead Sponsor: Rambam Health Care Campus

Target Recruit Count: 200

Registration Number: NCT01266499

Locations: 🇮🇱
Rambam Mc, Haifa, Israel

Population Pharmacokinetic Study of Colistin in Patients Infected With Multiresistant Gram-negative Bacteria

Phase 1

Completed

Conditions: Gram-negative Bacteria

First Posted Date: 2010-02-02

Last Posted Date: 2016-10-11

Lead Sponsor: Poitiers University Hospital

Target Recruit Count: 200

Registration Number: NCT01060891

Locations: 🇫🇷
Poitiers University Hospital - 2 rue de la Milétrie, Poitiers, France

Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Phase 2

Completed

Conditions: Cystic Fibrosis
Pseudomonas Aeruginosa

First Posted Date: 2009-12-21

Last Posted Date: 2013-03-21

Lead Sponsor: University of Jena

Target Recruit Count: 10

Registration Number: NCT01035853

Locations: 🇩🇪
Universitäts-Kinderklinik, Tübingen, Baden-Würtemberg, Germany
🇩🇪
Mukoviszidosezentrum der Friedrich-Schiller-Universität, Jena, Thüringen, Germany
🇩🇪
CF-Zentrum, Hamburg, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy